Published in Gene Therapy Weekly, February 26th, 2004
According to a study from Australia, "antisense oligonucleotides are emerging as an exciting therapeutic strategy for treating skin diseases such as psoriasis. Potential antisense targets are proteins upregulated in psoriatic skin, in particular those associated with inflammation (intercellular adhesion molecule (ICAM)-1, interleukin (IL)-2 and -8), proliferation (insulin-like growth factor type I receptor (IGF-IR), epidermal growth factor (EGF)) and hyperangiogenesis (vascular endothelial growth factor (VEGF)). Whereas topical application and subsequent penetration of large oligonucleodies into normal skin...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.